A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies

Trial Profile

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Apr 2017

At a glance

  • Drugs INCB 52793 (Primary) ; Gemcitabine; Itacitinib; Paclitaxel
  • Indications Cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 18 Apr 2017 INCB052793 and itacitinib Combination Therapy is now added to the study which will be conducted into I/II phase. Also responce rate as a end-point is now added thus focus changed from AR to TU + AR.Thus additional changes in official title and inclusion-exclusion criteria
    • 18 Apr 2017 Planned number of patients changed from 282 to 141.
    • 18 Apr 2017 Planned End Date changed from 1 Jul 2018 to 1 Jul 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top